Recent trends in brand-name and generic drug competition

Journal of Medical Economics

Volumn 17, Issue 3, 2014, Pages 207-214

  Grabowski, Henry ^a   Long, Genia ^b   Mortimer, Richard ^b  

^a DUKE UNIVERSITY   (United States)

^b ANALYSIS GROUP   (United States)

Author keywords

Economic competition; Generic drugs; Pharmaceutical economics; Prescription drugs

Indexed keywords

GENERIC DRUG;

ARTICLE; DOCUMENTATION; DRUG MANUFACTURE; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; PHARMACEUTICAL COMPETITION;

DRUG INDUSTRY; DRUGS, GENERIC; HUMANS; PATENTS AS TOPIC; PRESCRIPTION DRUGS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84896730369     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.873723     Document Type: Article

References (12)

1. Grabowski H, Vernon J. Longer patents for lower imitation barriers: The 1984 drug act. Amer Econ Rev 1986;76:195-8
2. Berndt E. Pharmaceuticals in U.S. health care: Determinants of quantity and price. J Econ Perspect 2002;16:45-66
3. Science and Data Policy, Assistant Secretary for Planning and Evaluation. Expanding the Use of Generic Drugs. Washington, DC. 2010. Available at: Http://aspe.hhs.gov/sp/reports/2010/genericdrugs/ib.pdf. Accessed May 15, 2013
4. IMS Institute for Healthcare Informatics. Declining Medicine Use and Costs: For Better or Worse Parsippany, NJ. 2013. Available at: Http://www.imshealth. com/portal/site/imshealth/menuitem.762a961826aad98f53c75 3c71ad8c22a/vgnextoid=5b21ee0a8e631410VgnVCM10000076192c a2RCRD. Accessed May 15, 2013
5. The Congress of the United States, Congressional Budget Office. How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. Washington, DC. 1998. Available at: Http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/6xx/doc655/pharm.pdf. Accessed May 15, 2013
6. Grabowski H, Kyle M. Generic competition and market exclusivity periods in pharmaceuticals. Manage Decis Econ 2007;28:491-502
7. Grabowski H, Kyle M, Mortimer R, et al. Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act. Health Affairs 2011;30:2157-66
8. U.S. Food and Drug Administration. Abbreviated New Drug Application and Generics. 2013:1-42. Available at: Http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/App rovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM293268. pdf. Accessed May 15, 2013
9. Panattoni LE. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms. J Health Econ 2011;30:126-45
10. Smith K, Gleklen K. Generic drugmakers will challenge patents even when they have a 97% chance of losing: The FTC Report that K-Dur Ignored. Boston, MA: CPI Antitrust Chronicle, 2012. www.competitionpolicyinternational. com/generic-drugmakers-will-challenge-patents-even-when-they-have-a-97-chance- of-losing-the-ftc-report-that-k-dur-ignored/. Accessed October 3, 2013
11. Greene A, Steadman DD. Analyzing Litigation Success Rates. Pharmaceuticals. 2010;(212):1-24. http://www.aipla.org/committees/com mittee-pages/FDA/CommitteeDocuments/MeetingMaterials/2010SpringMeetin g/AnalyzingLitigationSuccessRates.pdf. Accessed May 15, 2013
12. Glass G. Legal defenses and outcomes in Paragraph IV Patent Litigation. J Generic Med 2013;10:4-13